Evonik's Strategic Shifts Fail to Impress Investors

Evonik's stock fell over 3% after results. It met 2025 EBITDA guidance but revenue declined. The firm announced a new variable dividend policy and a major cost-cutting program.

Despite meeting its earnings guidance and announcing significant strategic changes, Evonik's shares faced a sharp sell-off. The stock declined by more than 3% on the day of the results release, trading at €13.48, as the market delivered a negative verdict on the company's latest moves.

Financial Performance: Profit Target Met Amid Revenue Decline

For the 2025 fiscal year, the specialty chemicals group reported adjusted EBITDA of €1.874 billion, falling from €2.065 billion in the prior year. This figure landed within the company's forecast range. Group net income showed improvement, rising to €265 million. However, total revenue contracted by 7% to €14.1 billion. The trading volume of nearly 1.5 million shares on the announcement day was well above average, indicating strong selling pressure from investors.

A New, Flexible Dividend Policy

Evonik is overhauling its shareholder returns framework. Moving forward, starting with the 2026 financial year, the company will adopt a variable dividend policy, planning to distribute between 40% and 60% of its adjusted net income. This range offers management greater flexibility but reduces predictability for shareholders. As a transitional measure for 2025, the board has proposed a dividend of €1.00 per share. Shareholders will vote on this proposal at the Annual General Meeting on June 3. At the current share price, this payout implies a yield of 7.37%.

Price Hike for Key Product MetAMINO®

Concurrent with its earnings release, Evonik's animal nutrition business unit announced a global net price increase of 10% for its key product, MetAMINO®, effective March 5. This move is aimed at bolstering profitability within the Advanced Technologies segment, which includes the unit. The segment faced margin pressure in 2025, with its adjusted EBITDA decreasing by 8% to €944 million and the corresponding margin dropping from 16.8% to 15.8%. The price adjustment is a strategy to stabilize earnings in a challenging environment for volume growth.

2026 Outlook: Revised Revenue Guidance

For the current year, Evonik has reaffirmed its adjusted EBITDA forecast of between €1.7 billion and €2.0 billion. In contrast, management has revised its revenue expectations downward. The company now anticipates sales of €13.5 billion to €14.5 billion, a narrower band than previously communicated. This adjustment reflects ongoing pressures in certain business areas. Medium-term, the group is targeting a Return on Capital Employed (ROCE) of 11%, a significant climb from the 6.1% recorded in 2025.

Transformation Program Nears Completion

The "Evonik Tailor Made" transformation initiative is progressing toward its conclusion in 2026. Upon completion, the program is expected to generate annual savings of €400 million. Approximately 80% of these savings, or around €320 million, will come from workforce reductions. The company plans to cut up to 2,000 positions globally, with roughly 1,500 of those in Germany.

Since April 2025, Evonik has operated under a two-segment structure. The Custom Solutions segment reported a 4% decline in revenue to €5.49 billion. An ongoing concern for the company is the vacant position of Chief Financial Officer, a situation creating internal and external uncertainty.

Investor attention now turns to the Q1 2026 quarterly report due on May 8. This update will provide the first clear indication of whether the dual strategy of targeted price increases and strict cost discipline can successfully offset declining sales and help the company achieve its full-year targets.